Leah Rush Cann

Leah Rush Cann is the Founder and CEO of Leah Rush Cann Consulting, LLC, an oncology and cancer research consulting organization. Previously she was a Managing Director and Senior Biotechnology Analyst at Oppenheimer & Co. in the Life Sciences practice. She began her career as a research scientist with Memtec Corporation and moved to Wall Street in 1992, where she was a research analyst with Oppenheimer for nearly nine years. Ms. Cann was a healthcare analyst and portfolio manager for the Boston-based asset manager, Cadence Capital, and later the senior biotechnology analyst for Wachovia Securities. Twice recognized as an All-Star analyst by the Wall Street Journal. Ms. Cann received a BA in Art History and Chemistry and an MBA from Stetson University. She was a post-baccalaureate at the College of William and Mary and a post-graduate at Columbia University. She has served on the Board of Directors of MEI Pharma, Inc. and currently serves on the Advisory Board of the RNA Institute at Beth Israel Deaconess Medical Center’s Cancer Center.